State Street Corp increased its position in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 1.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,265,089 shares of the company’s stock after buying an additional 20,834 shares during the period. State Street Corp owned 1.86% of Diplomat Pharmacy worth $18,718,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in DPLO. Royal Bank of Canada increased its position in shares of Diplomat Pharmacy by 25.0% during the 2nd quarter. Royal Bank of Canada now owns 35,266 shares of the company’s stock worth $521,000 after purchasing an additional 7,056 shares in the last quarter. State of Wisconsin Investment Board grew its holdings in Diplomat Pharmacy by 9.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 278,000 shares of the company’s stock worth $4,114,000 after acquiring an additional 25,000 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in Diplomat Pharmacy by 19.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 272,979 shares of the company’s stock worth $4,043,000 after acquiring an additional 44,135 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in Diplomat Pharmacy by 54.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 86,544 shares of the company’s stock worth $1,281,000 after acquiring an additional 30,645 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Diplomat Pharmacy by 11.4% during the 2nd quarter. New York State Common Retirement Fund now owns 52,900 shares of the company’s stock worth $783,000 after acquiring an additional 5,399 shares during the last quarter. Hedge funds and other institutional investors own 72.48% of the company’s stock.
In related news, President Joel Saban purchased 10,000 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was acquired at an average cost of $15.24 per share, with a total value of $152,400.00. Following the transaction, the president now owns 12,000 shares of the company’s stock, valued at approximately $182,880. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Atul Kavthekar purchased 2,000 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was bought at an average cost of $15.00 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares in the company, valued at approximately $30,000. The disclosure for this purchase can be found here. Insiders purchased 15,000 shares of company stock worth $228,780 over the last quarter. 30.20% of the stock is currently owned by company insiders.
DPLO has been the topic of several recent research reports. BidaskClub raised shares of Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Needham & Company LLC reissued a “buy” rating and set a $23.75 price objective (up previously from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. Mizuho set a $16.00 price objective on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Tuesday, October 24th. Zacks Investment Research raised shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective on the stock in a research note on Tuesday, October 10th. Finally, Leerink Swann raised their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a report on Tuesday, November 7th. Six equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $20.39.
Diplomat Pharmacy, Inc. (DPLO) traded up $0.48 during mid-day trading on Monday, reaching $18.21. The company had a trading volume of 949,968 shares, compared to its average volume of 812,209. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34. The firm has a market capitalization of $1,221.12, a P/E ratio of 23.03, a PEG ratio of 3.19 and a beta of 0.61. Diplomat Pharmacy, Inc. has a fifty-two week low of $12.25 and a fifty-two week high of $21.99.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the prior year, the firm posted $0.21 earnings per share. The firm’s revenue was down 4.8% compared to the same quarter last year. analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “State Street Corp Has $18.72 Million Holdings in Diplomat Pharmacy, Inc. (DPLO)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/diplomat-pharmacy-inc-dplo-shares-bought-by-state-street-corp.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.